Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MADRIGAL PHARMACEUTICALS, INC. Director's Dealing 2012

Jul 3, 2012

30608_dirs_2012-07-03_07561f00-50ed-4f23-871f-d8a0b83c070b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SYNTA PHARMACEUTICALS CORP (SNTA)
CIK: 0001157601
Period of Report: 2012-07-01

Reporting Person: KUFE DONALD W (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-07-01 Common Stock A 7312 Acquired 7312 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-07-01 Director Stock Option (Right to Buy) $5.47 A 10000 Acquired 2022-07-01 Common Stock (10000) Direct

Footnotes

F1: Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as director of the Issuer on such date.

F2: The option vests as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as a director of the Issuer on such date.